Table 1.
The basic characteristics and main outcomes of the 8 included randomized controlled trials.
| Study ID | Phase | Tumor Type | Treatment groups |
Line | Number of patients |
Median Follow-up (month) | Overall Survival |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention group | Control group | Total | With LM (%) |
Without LM (%) |
HR (95% CI) for Patients with LM | HR (95% CI) for patients without LM | |||||
| IMpower130 | 3 | Non-squamous Non-small-cell Lung Cancer | Atezolizumab + Carboplatin + Nab-paclitaxel | Carboplatin + Nab-paclitaxel | 1 | 679 | 100(15%) | 579(85%) | 18.5 vs 18.8 | 1.04 (0.63 ~ 1.72) | 0.73 (0.57 ~ 0.92) |
| IMvigor211 | 3 | Urothelial Carcinoma | Atezolizumab | *Investigator’s choice Chemotherapy | >1 | 931 | 268(29%) | 663(71%) | 17.3 | 0.84(0.64 ~ 1.09) | 0.83(0.69 ~ 1.0) |
| IMpower133 | 3 | Small-Cell Lung Cancer | Atezolizumab + Carboplatin + Etoposide | Placebo + Carboplatin + Etoposide |
1 | 403 | 149 (37%) | 254 (63%) | 13.9 | 0.81 (0.55 ~ 1.20) | 0.64 (0.45 ~ 0.90) |
| KEYNOTE-045 | 3 | Urothelial Carcinoma | Pembrolizumab | *Investigator’s choice Chemotherapy | >1 | 541 | 186(34%) | 355(66%) | 14.1 | 0.85 (0.61 ~ 1.20) | 0.67 (0.50 ~ 0.89) |
| ATTRACTION-2 | 3 | Gastric or Gastro-esophageal Junction Cancer | Nivolumab | placebo | >1 | 493 | 106(22%) | 387(78%) | 8.87 vs 8.59 | 0.67 (0.42 ~ 1.07) | 0.64 (0.50 ~ 0.81) |
| CheckMate025 | 3 | Renal-Cell Carcinoma | Nivolumab | Everolimus | >1 | 821 | 187 (23%) | 634(77%) | 22 | 0.81 (0.55–1.18) | 0.73 (0.58–0.92) |
| Checkmate214 | 3 | Renal-Cell Carcinoma | Nivolumab + Ipilimumab | Sunitinib | 1 | 847 | 177(21%) | 670(79%) | 25.2 | 0.64 (0.42–0.96) | 0.66 (0.51–0.85) |
| IMpower132 | 3 | Non-squamous Non-small-cell Lung Cancer | Atezolizumab + Carboplatin+ Cisplatin/Pemetrexed | Carboplatin + Cisplatin/Pemetrexed | 1 | 578 | 73(13%) | 505(87%) | 14.8 | 0.99 (0.57–1.70) | 0.76 (0.59–0.98) |
PD-1: programmed cell death 1; PD-L1: programmed cell death ligand 1; LM: liver metastases; HR: hazard ratios; CI: confidence interval: *Investigator’s choice chemotherapy: paclitaxel, docetaxel, or vinflunine.